[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100353555":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":31,"centralContacts":36,"locations":46,"responsibleParty":68,"collaborators":71,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":25,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":25,"overallStatus":48,"whyStopped":25,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"University of Virginia","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Exercise Alone","EXPERIMENTAL","16 weeks of treatment",[13],"Other: Exercise",{"label":15,"type":10,"description":11,"interventionNames":16},"Liraglutide alone",[17],"Drug: Liraglutide",{"label":19,"type":10,"description":11,"interventionNames":20},"Exercise + Liraglutide",[13,17],[22,26],{"type":6,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"Exercise",[19,9],null,{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":25},"DRUG","Liraglutide","16 weeks of Liraglutide",[19,15],[32],{"name":33,"affiliation":34,"role":35},"Zhenqi Liu, MD","University of Virginia, Department of Endocrinoolgy","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":25,"email":41},"Lee Hartline, MEd","CONTACT","434-924-5247","lmh9d@virginia.eud",{"name":43,"role":39,"phone":44,"phoneExt":25,"email":45},"Linda Jahn, RN, MEd","434-924-1134","las6e@virginia.edu",[47],{"facility":5,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"RECRUITING","Charlottesville","Virginia","22906","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-78.47668,38.02931,{"lat":58,"lon":57},[61,64],{"name":33,"role":39,"phone":62,"phoneExt":25,"email":63},"434-243-2603","zl3e@virginia.edu",{"name":65,"role":39,"phone":66,"phoneExt":25,"email":67},"Eugene Barrett, MD, PhD","434-924-1175","ejb8x@virginia.edu",{"type":35,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Zhenqi Liu","Professor and Chief, Division of Endocrinology and Metabolism",[72,74],{"name":73,"class":6},"American Diabetes Association",{"name":75,"class":76},"National Institutes of Health (NIH)","NIH","100353555","phase-4-effect-of-exercise-andor-liraglutide-on-vascular-dysfunction-and-insulin-sensitivity-in-type-2-diabetes--zql007-100353555",false,"NCT03883412","Effect of Exercise and\u002For Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)","ZQL007","Inclusion Criteria:\n\n* Age 21-60\n* A1C ≤ 8.5%\n* Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)\n* On stable dose of oral hypoglycemic agents \\>4 months\n* On stable dose of other medications for \\>4 months\n\nExclusion Criteria:\n\n* Taking Insulin\n* Smoking presently or in the past 6 months\n* BP \\>160\u002F90\n* BMI \\>35\n* Family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome\n* History of congestive heart failure, ischemic heart disease, severe pulmonary disease, liver or kidney disease.\n* Any vascular disease such as myocardial infarction, stroke, peripheral vascular disease\n* Presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam by PI).\n* Pregnant or breastfeeding.\n* Known hypersensitivity to perflutren (contained in Definity)",true,"ALL","21 Years","60 Years",{"count":89,"type":90},60,"ESTIMATED","INTERVENTIONAL",[93],"PHASE4","The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.",[96],"Type2 Diabetes","2026-08-10",{"date":99,"type":100},"2026-08-12","ACTUAL",{"date":102,"type":100},"2019-02-28",{"date":104,"type":90},"2027-12",{"name":5,"class":6},1]